Dr. Cabanillas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2007 - 2009
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1998 - 2001
University of Puerto Rico School of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2026
GA State Medical License 2023 - 2026
TN State Medical License 2022 - 2026
TX State Medical License 2001 - 2026
WA State Medical License 2022 - 2026
LA State Medical License 2022 - 2025- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- Join now to see all
Clinical Trials
- A Study of Actonel for the Prevention of Bone Loss Start of enrollment: 2004 Feb 01
- The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer Start of enrollment: 2012 Nov 01
- Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Start of enrollment: 2013 May 08
- Join now to see all
Publications & Presentations
PubMed
- 505 citationsDabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid CancerVivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Jae Yong Cho, Jan H.M. Schellens
Journal of Clinical Oncology. 2018-01-01 - 26 citationsSurgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFMutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.Xiao Zhao, Jennifer Rui Wang, Ramona Dadu, Naifa Lamki Busaidy, Lei Xu
Thyroid. 2023-04-01 - 4 citationsReturn of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced T...Amanda Silver Karcioglu, Amr H Abdelhamid Ahmed, Zipei Feng, Marika Russell, David C Shonka Jr
Thyroid. 2023-10-01
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah,..., The New England Journal of Medicine
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineThinh Vu, Naifa L Busaidy, Maria E Cabanillas, Steven G Waguespack, Steven I Sherman, Mark Zafereo, The Journal of Clinical Endocrinology and Metabolism
- Selective RET Kinase Inhibition for Patients with RET-Altered CancersL J Wirth, N L Busaidy, M E Cabanillas, Annals of Oncology
Lectures
- New Medical Options for the Treatment of Advanced Thyroid CancerENDO 2019 - New Orleans, LA - 3/24/2019
- Advanced Thyroid Cancers: New Insights and TreatmentsENDO 2019 - New Orleans, LA - 3/25/2019
- From Thyroid Nodules to Thyroid Cancer: Diagnosis and TreatmentENDO 2019 - New Orleans, LA - 3/25/2019
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
Pembrolizumab Boosts Survival in Anaplastic Thyroid CancerNovember 5th, 2024- Atezolizumab plus Targeted Agents Shows Promise in Anaplastic Thyroid CarcinomaOctober 28th, 2024
- New Hope Against a Rare, Aggressive Form of Thyroid CancerOctober 28th, 2024
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
